Filana Therapeutics
FLNA
153 hedge funds and large institutions have $332M invested in Filana Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 41 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 36
27% more call options, than puts
Call options by funds: $133M | Put options by funds: $105M
0.74% more ownership
Funds ownership: 26.21% → 26.96% (+0.74%)
12% less funds holding
Funds holding: 174 → 153 (-21)
24% less capital invested
Capital invested by funds: $439M → $332M (-$106M)
39% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$5.9M |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$3.76M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.13M |
| 4 |
Goldman Sachs
New York
|
+$2.96M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.58M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$5.93M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
-$4.81M |
| 4 |
TI
Think Investments
San Francisco,
California
|
-$4.67M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.44M |
FLNA Hedge Fund Activity: Q4 2022 in Review
153 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2022, worth a combined $332M — down 24% from $439M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of FLNA and 25 opened new positions — a net loss of 16 holders — while 36 trimmed existing stakes and 50 added.
The largest buyer was Invesco, adding an estimated $5.9M. The largest seller was Marshall Wace, exiting entirely with an estimated $6.58M sold.
- 153 institutional investors held Filana Therapeutics (FLNA) as of Q4 2022, down from 174 in Q3 2022.
- Funds reported $332M of Filana Therapeutics stock for Q4 2022, down 24% quarter-over-quarter.
- 25 funds opened new Filana Therapeutics positions in Q4 2022 and 41 closed out, a net change of -16 holders.
- The largest Filana Therapeutics buyer in Q4 2022 was Invesco, an estimated $5.9M added.
- The largest Filana Therapeutics seller in Q4 2022 was Marshall Wace, an estimated $6.58M sold.
Based on aggregated 13F filings for Q4 2022.